Are China Hospital Purchases Slowing? Ask Mindray
This article was originally published in The Gray Sheet
Executive Summary
China’s largest medical device maker surprised everyone by posting overall second-quarter net revenue growth of 9 percent, to $334.5 million, amid challenging market conditions. It expects a further recovery in the second half, but conditions at home remain difficult.
You may also be interested in...
The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.
Syngene COO On Delivering Cost Gains For mRNA Products
Syngene’s COO, Mahesh Bhalgat, tells Scrip the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company' capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.